MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months $(TTM)$ ended June 30, 2026. Key highlights include:

 
                                                                         % Change 
                             % Change              % Change              vs. TTM 
                                vs.                   vs.     TTM Jun    Jun 30, 
(CAD)             Q2 2026     Q2 2025   H1 2026     H1 2025   30, 2026     2025 
---------------  ----------  --------  ----------  --------  ----------  -------- 
Pharmaceutical 
 Sales           11,110,365      +14%  21,913,472       +7%  42,325,508      +11% 
Oral Health 
 Sales            8,224,402       n/a  11,209,375       n/a  11,209,375       n/a 
Insecticide 
 Sales              537,996      +32%     658,098       -5%   2,139,789      +51% 
---------------  ----------  --------  ----------  --------  ----------  -------- 
Total Company 
 Sales           19,872,763      +95%  33,780,945      +60%  55,674,672      +41% 
---------------  ----------  --------  ----------  --------  ----------  -------- 
EBITDA(1)         4,976,253      +80%   8,615,339      +45%  14,776,299      +34% 
---------------  ----------  --------  ----------  --------  ----------  -------- 
Net Income 
 After Taxes 
 (NIAT)           2,849,437      +41%   5,194,256      +20%   9,868,384      +19% 
---------------  ----------  --------  ----------  --------  ----------  -------- 
Fully Diluted 
 EPS                   0.25      +39%        0.45      +19%        0.85      +18% 
---------------  ----------  --------  ----------  --------  ----------  -------- 
 
 
   -- Q2 2026 was first full quarter of financial results contributed by Oral 
      Health segment following March 1, 2026 acquisition of Oral Science Inc.: 
 
          -- $8.2 million sales 
 
          -- $1.5 million EBITDA1 
 
          -- $1.1 million NIAT (before $0.75 million amortization expense on 
             acquired intangible assets) 
 
   -- Q2 2026 consolidated EBITDA1 margin:  25% to sales (26% to sales - 
      adjusted for one-time acquisition costs) 
 
   -- H1 2026 consolidated EBITDA1 margin:  26% to sales (27% to sales - 
      adjusted for one-time acquisition costs) 
 
   -- Return on Average Equity for the trailing twelve months ('TTM') ended 
      June 30, 2026 was 24%, increasing from 23% for TTM June 30, 2025 
 
   -- During H1 2026, repurchased and cancelled a total of 218,500 common 
      shares under a Normal Course Issuer Bid (NCIB) 
 
   -- Paid quarterly cash dividends of $0.055 per common share on March 13, 
      2026 and June 15, 2026 
 
   -- Declared subsequent cash dividend of $0.055 per common share to be paid 
      on September 15, 2026 

"We are very pleased with the first full quarter of operating results delivered by our new Oral Health segment in Q2 2026," commented Mr. René Goehrum, President and CEO of BioSyent. "The added sales and profit from the Oral Health segment when combined with continued growth in our existing Pharmaceutical segment, both in Canada and internationally, resulted in total Company quarterly sales and EBITDA(1) growth of 95% and 80%, respectively, over the comparative quarter. With H1 2026 operating cash flows from the Oral Health segment of $1.3 million since the March 1st acquisition date combined with $3.9 million in H1 2026 operating cash flows from our Pharmaceutical and Insecticide businesses, we continued to invest in growing all of our businesses in H1 2026 in addition to paying down our short term acquisition debt, buying back shares under our Normal Course Issuer Bid, and paying regular quarterly dividends. Though we continue to face economic uncertainty in Canada and geopolitical instability internationally, we are well-positioned with a strong balance sheet and more diversified product portfolio, to continue to deliver on our strategic priorities of profitable growth, portfolio diversification and long-term value creation for our shareholders."

The CEO's presentation on the Q2 2026 Results is available at the following link: www.biosyent.com/investors/

The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30, 2026 and 2025 will be posted on www.sedarplus.ca on August 20, 2026.

The Company further announces that its Board of Directors has approved a grant of 590 Restricted Share Units ("RSUs") to certain employees of the Company pursuant to the Company's RSU Plan. These RSUs will fully vest within three years on the third anniversary of the applicable grant date.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

As of the date of this press release, the Company has 11,308,835 common shares outstanding.

 
 
                                        BioSyent Inc. 
                     Interim Unaudited Condensed Consolidated Statements 
                                   of Comprehensive Income 
 
In Canadian Dollars    Q2 2026     Q2 2025    % Change     H1 2026      H1 2025    % Change 
--------------------  ----------  ----------  --------  -------------  ----------  -------- 
Net Revenues          19,872,763  10,179,296      +95%     33,780,945  21,158,256      +60% 
Cost of Goods Sold     5,902,946   2,266,734     +160%      9,642,892   4,908,502      +96% 
Gross Profit          13,969,817   7,912,562      +77%     24,138,053  16,249,754      +49% 
Operating Expenses 
 and Finance 
 Income/Costs          9,999,709   5,166,751      +94%     16,882,644  10,347,572      +63% 
Net Income Before 
 Tax                   3,970,108   2,745,811      +45%  7,255,409(++)   5,902,182      +23% 
Tax (including 
 Deferred Tax)         1,120,671     727,640      +54%      2,061,153   1,564,078      +32% 
Net Income After Tax   2,849,437   2,018,171      +41%  5,194,256(++)   4,338,104      +20% 
Net Income After Tax 
 % to Net Revenues           14%         20%                      15%         21% 
EBITDA(1)              4,976,253   2,760,149      +80%      8,615,339   5,961,796      +45% 
EBITDA(1) % to Net 
 Revenues                    25%         27%                      26%         28% 
--------------------  ----------  ----------  --------  -------------  ----------  ---------- 
 
 

Net of $750,000 amortization expense on intangible assets recognized in acquisition of Oral Science Inc.

++ Net of $1,000,000 amortization expense on intangible assets recognized in acquisition of Oral Science Inc.

 
 
                              BioSyent Inc. 
           Interim Unaudited Condensed Consolidated Statements 
                           of Financial Position 
 
 
                   AS AT   June 30, 2026    December 31, 2025    % Change 
                          ---------------  -------------------  ---------- 
ASSETS 
 
Cash, cash equivalents 
 and short-term 
 investments               $    8,942,833   $       28,651,823      -62% 
Trade and other 
 receivables                    6,697,930            4,456,562       68% 
Inventory                      10,743,336            6,416,204       76% 
Prepaid expenses and 
 deposits                       2,071,388              187,977      738% 
Derivative asset                   11,120                    -         - 
Loans receivable - 
 current                           72,118               80,395      -21% 
                              -----------      ---------------  -------- 
CURRENT ASSETS                 28,538,725           39,792,961      -21% 
                              -----------      ---------------  -------- 
 
Long term investments           3,293,957            3,293,957        0% 
Loans receivable -- 
 non-current                            -               61,799        0% 
Deferred tax asset                502,662              510,932        3% 
Property and equipment          1,571,171              982,737       74% 
Intangible assets              22,757,649            4,797,073      355% 
Goodwill                        3,796,739                    -         - 
                              -----------      ---------------  -------- 
TOTAL NON CURRENT ASSETS       31,992,178            9,646,498      223% 
                              -----------      ---------------  -------- 
TOTAL ASSETS               $   60,460,903   $       49,439,459       26% 
                              ===========      ===============  ======== 
 
LIABILITIES AND 
SHAREHOLDERS' EQUITY 
 
CURRENT LIABILITIES        $    7,951,771   $        7,215,608       49% 
SHORT TERM DEBT                 2,000,000                    -         - 
CONTINGENT CONSIDERATION        3,845,837                    -         - 
NON CURRENT LIABILITIES           820,315              758,345       23% 
Total Equity                   45,842,980           41,465,506        9% 
                              -----------      ---------------  -------- 
TOTAL LIABILITIES AND 
 SHAREHOLDERS' EQUITY      $   60,460,903   $       49,439,459       26% 
                              ===========      ===============  ======== 
 
 
   1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any 
      standardized meaning under International Financial Reporting Standards